News | Jan 24, 2008

Clinical Data and Affymetrix Announce Marketing Agreement for New Drug Metabolism Service

- Cogenics/Epidauros to Provide Worldwide Services Using Affymetrix’ DMET Early Access Solution — Pharmaceutical Customers to Have Enhanced Tools to Understand Patient-to-Patient Variability in Pharmacokinetic Responses to Drugs -

By: Clinical Data/Affymetrix

NEWTON, Mass. and SANTA CLARA, Calif.– January 24, 2008 – Clinical Data Inc. (NASDAQ: CLDA) and Affymetrix Inc. (NASDAQ: AFFX) today announced a marketing agreement for a new drug metabolism service using the Affymetrix Drug Metabolizing Enzymes and Transporter (DMET) Early Access solution. Cogenics and Epidauros Biotechnologie AG, both subsidiaries of Clinical Data Inc., will offer the DMET services on a global basis, with limited exclusivity in Europe. Affymetrix (DMET) Early Access solution is currently the world’s most comprehensive method for assaying the genetics of drug metabolism. The service will enable pharmaceutical customers to generate comprehensive genetic profiles of a patient’s metabolic status to gain a better understanding of pharmacokinetic drug response. In a separate release issued today, Affymetrix announced the availability of its DMET Early Access Solution.

For more information on Cogenics’ and Epidauros’ DMET solutions, please call 1-877-226-4364 (U.S.) or +49 8158 9985 0 (E.U.), or email

sales@cogenics.com or contact@epidauros.com.

[to read more see attached PDF file]

For More Information

File(s)
	38_20080124_CLDA_AFFX_release_FINAL.pdf	Size: 129 K